AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9200654
Drug: Atenolol 50-100
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50-100 mg/day
Trial: 8256699
Drug: Extended-release isosorbide
RxNorm normalized name: isosorbide Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release isosorbide mononitrate 30, 60, 120 or 240 mg once daily
Trial: 8256699
Drug: Extended-release isosorbide
RxNorm normalized name: isosorbide Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release isosorbide mononitrate 120 or 240 mg once daily
Trial: 2863998
Drug: Atracurium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.6 mg/kg (group A; n = 11)
Trial: 2863998
Drug: Fazadinium 1
RxNorm normalized name: fazadinium bromide
DrugBank: Fazadinium bromide (DB13745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fazadinium 1 mg/kg (group F; n = 11)
Trial: 25040799
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TA) 3 g a day
Trial: 16100174
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (intermittent nCPAP 10 cm H2O for 10 min every 4 h)
Trial: 1755531
Drug: NLA in
RxNorm normalized name: Ngenla Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NLA in combination with epidural opiate analgesia (group 2)
Trial: 1755531
Drug: NLA in
RxNorm normalized name: Ngenla Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NLA in combination with local anesthesia (group 3)
Trial: 1755531
Drug: Epidurally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidurally administered morphine (group 2)
Trial: 6804222
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg DPM (dipropylacetamide) taken after a standard meal
Trial: 6804222
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg DPM (dipropylacetamide) taken in a fasting state
Trial: 24349052
Drug: Ataluren 10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ataluren 10, 10, 20 mg/kg
Trial: 22550833
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose pantoprazole bolus injections (40 mg twice daily for 7 days)
Trial: 22550833
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of pantoprazole (8 mg per hour for first 3 days, then 40 mg bolus twice daily for 4-7 days)
Trial: 22550833
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose pantoprazole bolus injections
Trial: 22550833
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of pantoprazole
Trial: 17086540
Drug: Dysfunctional Attitude
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dysfunctional Attitude Scale (DAS) scores at the beginning of continuation treatment
Trial: 15022126
Drug: Once-daily 2.5-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily 2.5-mg rhDNase
Trial: 15022126
Drug: Alternate-day 2.5-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate-day 2.5-mg rhDNase
Trial: 15022126
Drug: Twice-daily 5
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily 5 ml of 7% hypertonic saline (HS)
Trial: 9772930
Drug: Benazepril 10
RxNorm normalized name: benazepril 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril 10 mg once daily for 8 weeks
Trial: 9772930
Drug: Benazepril 10
RxNorm normalized name: benazepril 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril 10 mg once daily for 4 weeks, then Hydrochlorothiazide 12.5 mg once daily for the last 4 weeks if DBP > 90 mmHg
Trial: 8170729
Drug: PRP-T with
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP-T with diphtheria toxoid vaccine
Trial: 8170729
Drug: PRP-OMP with
RxNorm normalized name: Hib (PRP-OMP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP-OMP with diphtheria-tetanus toxoid vaccine
Trial: 8170729
Drug: Diphtheria-tetanus toxoid
RxNorm normalized name: diphtheria-tetanus toxoids (DT) ped
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphtheria-tetanus toxoid vaccine
Trial: 12787692
Drug: 100% oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% oxygen (treatment group)
Trial: 12579906
Drug: Single plate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single plate Molteno implant
Trial: 6387183
Drug: 1-day treatment
RxNorm normalized name: 30 day Acne Treatment Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-day treatment regimen
Trial: 6387183
Drug: 10-day treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day treatment regimen
Trial: 24680372
Drug: Suvorexant (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suvorexant (40 mg for patients younger than 65 years, 30 mg for patients aged 65 years or older)
Trial: 22508924
Drug: 5 S's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 S's with sucrose (24% oral sucrose)
Trial: 22508924
Drug: Sucrose alone
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose alone (2 mL of 24% oral sucrose)
Trial: 22508924
Drug: Control (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (2 mL of water with standard-of-care comfort measures)
Trial: 20820114
Drug: Special mouth
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Special mouth care with essential oil (geranium, lavender, tea tree, and peppermint) applied twice daily for one week
Trial: 20820114
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline mouth care applied twice daily for one week
Trial: 18210330
Drug: tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tibolone 2.5 mg daily for 16 weeks
Trial: 18210330
Drug: 17beta-estradiol 2
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 17beta-estradiol 2 mg daily for 16 weeks
Trial: 22277987
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no hormone therapy)
Trial: 1667334
Drug: Baclofen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (10 mg PO at 0830h)
Trial: 6406531
Drug: Phosphate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate therapy (8.5 mmol/h or approximately 6 g phosphate/24 h)
Trial: 6406531
Drug: No phosphate
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No phosphate therapy (control group)
Trial: 24708645
Drug: First-line antiretroviral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line antiretroviral therapy (ART)
Trial: 24708645
Drug: Baseline genotyping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline genotyping for HIV drug resistance (HIVDR)
Trial: 23067427
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy component of CPT (n = 39)
Trial: 11454122
Drug: Oral estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estrogen (0.625 mg) combined with progesterone (2.5 mg)
Trial: 9548613
Drug: Lansoprazole, amoxicillin,
RxNorm normalized name: Lansoprazole, Amoxicillin, Clarithromycin KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole, amoxicillin, and clarithromycin triple therapy
Trial: 8047821
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of amoxycillin (3 g daily), metronidazole (1 g daily), and omeprazole (20 mg daily)
Trial: 19846027
Drug: Febuxostat (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat (80 mg or 120 mg daily)
Trial: 19846027
Drug: Allopurinol (300/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (300/100 mg/day)
Trial: 17464087
Drug: Autologous bone
RxNorm normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous bone marrow cell (BMC) transplantation and GM-CSF administration (n = 17, 14 days post-injury)
Trial: 17464087
Drug: Autologous bone
RxNorm normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous bone marrow cell (BMC) transplantation and GM-CSF administration (n = 6, between 14 days and 8 weeks post-injury)
Trial: 17464087
Drug: Autologous bone
RxNorm normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous bone marrow cell (BMC) transplantation and GM-CSF administration (n = 12, more than 8 weeks post-injury)
Trial: 15044639
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy plus autologous stem-cell transplantation
Trial: 15044639
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy plus autologous stem-cell transplantation (for high intermediate risk patients)
Trial: 8519044
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg or 20 mg
Trial: 8519044
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg plus hydrochlorothiazide 25 mg
Trial: 19000191
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (ER:YAG laser ablation + 5FU application + NB-UVB therapy)
Trial: 19000191
Drug: Mono-therapy (NB-UVB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mono-therapy (NB-UVB therapy only)
Trial: 16640106
Drug: 3TC (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3TC (4 mg/kg/day, max 100 mg) started simultaneously with IFN‐alpha2a for 6 months (group I)
Trial: 3440643
Drug: Microporous colestyramine
RxNorm normalized name: colestyramine
DrugBank: Cholestyramine (DB01432)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microporous colestyramine (MPC) 9 g/day
Trial: 3440643
Drug: Microporous colestyramine
RxNorm normalized name: colestyramine
DrugBank: Cholestyramine (DB01432)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microporous colestyramine (MPC) 12 g
Trial: 3440643
Drug: Microporous colestyramine
RxNorm normalized name: colestyramine
DrugBank: Cholestyramine (DB01432)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microporous colestyramine (MPC) 18 g
Trial: 26382589
Drug: Anti-TNF agents
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF agents
Trial: 26324284
Drug: Preemptive multimodal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive multimodal analgesic regimen (celecoxib, pregabalin, extended‐release oxycodone, and acetaminophen)
Trial: 15645698
Drug: Insulin dosage
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin dosage calculation device (IDC)
Trial: 12503831
Drug: Dothiepin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dothiepin (75 mg/day for 1 week followed by 150 mg/day for 4 weeks)
Trial: 9692699
Drug: Omeprazole 10
RxNorm normalized name: omeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 10 mg o.m.
Trial: 29535280
Drug: Aromatherapy (inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatherapy (inhalation of aroma oil blended with lavender, ylang-ylang, and neroli at a ratio of 4:2:1, twice before and after CAG)
Trial: 23725162
Drug: Transcatheter arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter arterial infusion (TAI)
Trial: 20605308
Drug: Implants with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants with platform switching (test)
Trial: 20605308
Drug: Control implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control implants with horizontally matching implant-abutment connection (control)
Trial: 20605308
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between test and control implants
Trial: 18206919
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg bremelanotide as an intranasal spray
Trial: 8625682
Drug: Milrinone loading
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milrinone loading dose of 25 micrograms/kg (LOW) followed by infusion of 0.5 microgram/kg/min
Trial: 8625682
Drug: Milrinone loading
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milrinone loading dose of 50 micrograms/kg (MED) followed by infusion of 0.5 microgram/kg/min
Trial: 8625682
Drug: Milrinone loading
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milrinone loading dose of 75 micrograms/kg (HIGH) followed by infusion of 0.5 microgram/kg/min
Trial: 8625682
Drug: Milrinone administration
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milrinone administration (all doses)
Trial: 6489414
Drug: Cisapride (novel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (novel enterokinetic agent)
Trial: 30708075
Drug: Intravenous adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous adrenaline
Trial: 25045257
Drug: Bisphosphonates (risedronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonates (risedronate 35 mg weekly) for 12 months
Trial: 25045257
Drug: Bisphosphonates along
RxNorm normalized name: methylene diphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonates along with nutritional supplementation (40 g protein, 600 kcal daily) for the first 6 months
Trial: 22278377
Drug: Sequential intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential intravenous 5‐FU at 800 mg/m2 for 5 days every 4 weeks followed by weekly PTX at 80 mg/m2
Trial: 22278377
Drug: Sequential S‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential S‐1 at 80 mg/m2 for 4 weeks and 2-week rest followed by PTX
Trial: 22278377
Drug: Concurrent intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent intravenous 5‐FU at 600 mg/m2 for 5 days and weekly PTX at 80 mg/m2 every 4 weeks
Trial: 22278377
Drug: Concurrent S‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent S‐1 for 14 days and PTX at 50 mg/m2 on days 1 and 8 every 3 weeks
Trial: 16275232
Drug: Ethinyl E2
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinyl E2 plus cyproterone acetate (0.01 mg + 3 mg/day)
Trial: 16275232
Drug: Norethindrone acetate
RxNorm normalized name: Norethindrone Acetate
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norethindrone acetate (2.5 mg/day)
Trial: 7755224
Drug: 300 mg/d
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/d of ursodeoxycholic acid
Trial: 7755224
Drug: 600 mg/d
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/d of ursodeoxycholic acid
Trial: 7755224
Drug: 1200 mg/d
RxNorm normalized name: Rebetron, single dose 1200 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg/d of ursodeoxycholic acid
Trial: 7840022
Drug: Biologically standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologically standardized extract of mites (active therapy)
Trial: 7840022
Drug: Saline buffered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline buffered solution (placebo)
Trial: 6775548
Drug: nasogastric saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nasogastric saline solution alone
Trial: 6775548
Drug: nasogastric saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nasogastric saline irrigation with oral mannitol
Trial: 6775548
Drug: oral mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral mannitol solution without saline
Trial: 31549889
Drug: Venetoclax 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax 400 mg daily plus rituximab
Trial: 23684438
Drug: 13 g
RxNorm normalized name: UREA 13 g TOPICAL TABLET [CLEAN-UP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13 g ground flaxseed
Trial: 19703665
Drug: NanoGreens vegetable
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NanoGreens vegetable supplement drink for 90 days
Trial: 16776704
Drug: Rizatriptan plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rizatriptan plus trimebutine (10 mg rizatriptan + 200 mg trimebutine)
Trial: 9611401
Drug: Insulin-dependent diabetic
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-dependent diabetic patients (European)
Trial: 9611401
Drug: Insulin-dependent diabetic
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-dependent diabetic patients with neuropathy (European)
Trial: 9611401
Drug: North African
RxNorm normalized name: African Pygeum extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: North African insulin-dependent diabetic patients
Trial: 8406644
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B (AMB) 1 mg/kg body weight on alternate days, starting with 0.05 mg/kg on the first day, total dose of 20 mg/kg
Trial: 8406644
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate (SAG) 20 mg/kg body weight, im daily for 30 days
Trial: 3534899
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg maprotiline and 9 mg haloperidol per day (for the first six days)
Trial: 3534899
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with maprotiline
Trial: 30220648
Drug: BFF MDI
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BFF MDI 320/10 µg
Trial: 30220648
Drug: BFF MDI
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BFF MDI 160/10 µg
Trial: 25344737
Drug: Flotation tank
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flotation tank treatment
Trial: 22733065
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg intravenous oseltamivir
Trial: 22733065
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg intravenous oseltamivir
Trial: 22733065
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg intravenous oseltamivir
Trial: 17218362
Drug: Acetazolamide (ACZ)
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide (ACZ) 250 mg, 3 doses, 8 hours apart
Trial: 12232483
Drug: Surgery with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery with total mesorectal excision for T1/2 N0 rectal cancers
Trial: 7663010
Drug: Serum levels
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum levels of intercellular adhesion molecule-1 at diagnosis in Hodgkin's disease patients
Trial: 7663010
Drug: Serum levels
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum levels of intercellular adhesion molecule-1 in complete remission
Trial: 7663010
Drug: Serum levels
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum levels of intercellular adhesion molecule-1 in patients with advanced disease who attained complete remission
Trial: 7663010
Drug: Serum levels
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum levels of intercellular adhesion molecule-1 in patients who failed to attain complete remission
Trial: 7663010
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of serum levels of intercellular adhesion molecule-1 with clinical features
Trial: 782976
Drug: Vaccine A
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine A (with galactose)